VigPanc
Clinical research
Hospital Alvaro Cunqueiro - IIS Galicia Sur
·Vigo ·

VigPanc is a recently formed multidisciplinary group born from our dedication to care, research and intellectual interest in the study and treatment of pancreatic tumors. We are witnessing every day the difficulty in its diagnosis and subsequent management, as well as its associated morbidity. Moreover, the current available treatments are insufficient, despite recent improvements, both from a professional and social point of view.
In Galicia, we have an incidence rate of pancreatic cancer of 22 per 100,000 inhabitants, with a total of 604 new cases in 2022, according to the AECC cancer observatory. In our Medical Oncology service at the Álvaro Cunqueiro Hospital, we had 56 first consultations of patients diagnosed with pancreatic cancer in 2022, a figure that is increasing every year.
In short, we intend to be a group with a clear vocation for translational research, born from the multidisciplinary meetings that are held weekly in our center and that have allowed us to discuss the real problems of our patients across specialties, as well as the interdisciplinary interaction mainly for care purposes, but increasingly with more interest for research purposes and to provide practical knowledge about this disease.

Lines:

  • Clinical: analysis of symptoms and signs present in pancreatic cancer, as well as the identification of prognostic factors for the evolution of the disease.
  • Treatments: Participation in clinical trials. Search for predictive factors of response.
  • Molecular biology and translational research: search for diagnostic, prognostic and predictive biomarkers of treatment response. Study of tissue biopsies and/or liquid biopsy. Use of multi-omics data, NGS and bioinformatics.
  • Prognostic factors of complications in pancreatic surgery. Multimodal rehabilitation

Main publications in pancreatic cancer:

  1. Ulla Rocha JL, Salgado A, Sardina Ferreiro R, et al. Neuroendocrine Gastroenteropancreatic Tumors: Where Are We? Surg Laparosc Endosc Percutan Tech. 2017; 27(1): 36-41. PMID: 27977507
  2. Fernández A, Salgado M, García A, et al. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study. BMC Cancer; 18(1): 1185. PMID: 30497432
  3. Oitabén A, Fonseca P, Villanueva MJ, et al. Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC. Cancers (Basel). 2022; 14(11): 2626.
Dr. Elena Gallardo
Rosana Simon

Principal Investigator

Group members

  • Paula González Villarroel
  • Alberto Garrido Fernández
  • Mónica Martínez Fernández
  • María Gallardo Gómez
  • Irene Alonso Álvarez
  • Sergio Estévez Fernández
  • Dra. Rebeca Fernandez Victoria

Other groups